RUNX1 and non-small cell lung carcinoma: Importantly, both macrophage‐specific and systemic inhibition of Runx1 effectively blocked the tumorigenesis of lung cancer in mice; suggesting Runx1 may represent a druggable target for preventing the formation of MMT‐driven tumor‐promoting CAFs in NSCLC.